Literature DB >> 17998935

HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.

A Toschi1, J Edelstein, P Rockwell, M Ohh, D A Foster.   

Abstract

Loss of the von Hippel-Lindau (VHL) tumor suppressor gene contributes to proliferative disorders including renal cell carcinoma. The consequence of VHL loss is increased levels of hypoxia-inducible factor-alpha (HIFalpha), which is targeted for proteolytic degradation by the VHL gene product pVHL. HIF is a transcription factor that increases the expression of factors critical for tumorigenesis in renal cell carcinoma. We report here another regulatory component of HIFalpha expression in renal cancer cells. Phospholipase D (PLD), which is commonly elevated in renal and other cancers, is required for elevated levels of both HIF1alpha and HIF2alpha in VHL-deficient renal cancer cells. The induction of both HIF1alpha and HIF2alpha by hypoxic mimetic conditions was also dependent on PLD in renal cancer cells with restored pVHL expression. The effect of PLD activity upon HIFalpha expression was at the level of translation. PLD activity also provides a survival signal that suppresses apoptosis induced by serum deprivation in the renal cancer cells. Suppression of HIF2alpha has been shown to reverse tumorigenesis with renal cancer cells. The finding here that HIF2alpha expression is dependent on PLD in renal cancer cells suggests that targeting PLD signals may represent an alternative therapeutic strategy for targeting HIF2alpha in renal cancers where HIF2alpha is critical for tumorigenesis and elevated PLD activity is common.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998935     DOI: 10.1038/sj.onc.1210927

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway.

Authors:  Donggon Lyo; Limei Xu; David A Foster
Journal:  Biochem Biophys Res Commun       Date:  2010-05-08       Impact factor: 3.575

Review 2.  Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.

Authors:  David A Foster
Journal:  Biochim Biophys Acta       Date:  2009-03-02

Review 3.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

4.  Reciprocal regulation of AMP-activated protein kinase and phospholipase D.

Authors:  Suman Mukhopadhyay; Mahesh Saqcena; Amrita Chatterjee; Avalon Garcia; Maria A Frias; David A Foster
Journal:  J Biol Chem       Date:  2015-01-29       Impact factor: 5.157

5.  High Expression of PhospholipaseD2 Induced by Hypoxia Promotes Proliferation of Colon Cancer Cells through Activating NF- κ Bp65 Signaling Pathway.

Authors:  Maoxi Liu; Kunli Du; Bo Jiang; Xingye Wu
Journal:  Pathol Oncol Res       Date:  2018-08-08       Impact factor: 3.201

Review 6.  Physiological and pathophysiological roles for phospholipase D.

Authors:  Rochelle K Nelson; Michael A Frohman
Journal:  J Lipid Res       Date:  2015-04-29       Impact factor: 5.922

7.  Correlation between BOLD-MRI and HIF expression level in renal carcinoma.

Authors:  Dong Li; Xingming Wang; Shuai Wang; Jie Cheng
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

8.  Inhibition of phospholipaseD2 increases hypoxia-induced human colon cancer cell apoptosis through inactivating of the PI3K/AKT signaling pathway.

Authors:  Maoxi Liu; Zhongxue Fu; Xingye Wu; Kunli Du; Shouru Zhang; Li Zeng
Journal:  Tumour Biol       Date:  2015-11-27

Review 9.  Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis.

Authors:  Julian Gomez-Cambronero
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

Review 10.  Targeting mTOR with rapamycin: one dose does not fit all.

Authors:  David A Foster; Alfredo Toschi
Journal:  Cell Cycle       Date:  2009-04-02       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.